[go: up one dir, main page]

EA201390146A1 - Антитела к матриксной металлопротеиназе 9 - Google Patents

Антитела к матриксной металлопротеиназе 9

Info

Publication number
EA201390146A1
EA201390146A1 EA201390146A EA201390146A EA201390146A1 EA 201390146 A1 EA201390146 A1 EA 201390146A1 EA 201390146 A EA201390146 A EA 201390146A EA 201390146 A EA201390146 A EA 201390146A EA 201390146 A1 EA201390146 A1 EA 201390146A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
matrix metalloproteinase
mmp9
functional fragment
binding proteins
Prior art date
Application number
EA201390146A
Other languages
English (en)
Other versions
EA031729B1 (ru
Inventor
Скотт Алан Макколи
Мария Вайзберг
Original Assignee
Джилид Байолоджикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джилид Байолоджикс, Инк. filed Critical Джилид Байолоджикс, Инк.
Publication of EA201390146A1 publication Critical patent/EA201390146A1/ru
Publication of EA031729B1 publication Critical patent/EA031729B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Настоящая заявка обеспечивает композиции и способы, в которых используют связывающие белки, например, антитела и их антиген-связывающие фрагменты, которые связываются с белком матриксной металлопротеиназы-9 (ММР9) (ММР9 также известна как желатиназа-В), причем указанный связывающие белки включают тяжелую цепь иммуноглобулина (Ig) (или ее функциональный фрагмент) и легкую цепь Ig (или ее функциональный фрагмент).
EA201390146A 2010-08-27 2011-08-26 Антитела к матриксной металлопротеиназе 9 EA031729B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37788610P 2010-08-27 2010-08-27
PCT/US2011/049448 WO2012027721A2 (en) 2010-08-27 2011-08-26 Antibodies to matrix metalloproteinase 9

Publications (2)

Publication Number Publication Date
EA201390146A1 true EA201390146A1 (ru) 2013-12-30
EA031729B1 EA031729B1 (ru) 2019-02-28

Family

ID=45724100

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390146A EA031729B1 (ru) 2010-08-27 2011-08-26 Антитела к матриксной металлопротеиназе 9

Country Status (29)

Country Link
US (7) US8377443B2 (ru)
EP (1) EP2608809B1 (ru)
JP (3) JP5878538B2 (ru)
KR (4) KR101827048B1 (ru)
CN (2) CN104530238B (ru)
AP (2) AP2016009448A0 (ru)
AU (1) AU2011293125B2 (ru)
BR (1) BR112013004579B1 (ru)
CA (1) CA2808418C (ru)
CL (1) CL2013000535A1 (ru)
CO (1) CO6680656A2 (ru)
CR (1) CR20130132A (ru)
EA (1) EA031729B1 (ru)
EC (1) ECSP13012525A (ru)
ES (1) ES2739505T3 (ru)
IL (2) IL224614A (ru)
MA (1) MA34527B1 (ru)
MX (1) MX342413B (ru)
NZ (2) NZ701444A (ru)
PE (1) PE20131376A1 (ru)
PH (2) PH12013500347A1 (ru)
PL (1) PL2608809T3 (ru)
PT (1) PT2608809T (ru)
SG (2) SG188224A1 (ru)
SI (1) SI2608809T1 (ru)
TR (1) TR201910348T4 (ru)
UA (1) UA109908C2 (ru)
WO (1) WO2012027721A2 (ru)
ZA (2) ZA201301338B (ru)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377443B2 (en) 2010-08-27 2013-02-19 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
HUE035281T2 (en) 2011-01-14 2018-05-02 Univ California Therapeutic antibodies against ror-1 protein and methods for use of same
EA201491599A1 (ru) * 2012-02-29 2015-05-29 Джилид Байолоджикс, Инк. Антитела к матриксной металлопротеиназе 9
US9550836B2 (en) * 2012-02-29 2017-01-24 Gilead Biologics, Inc. Method of detecting human matrix metalloproteinase 9 using antibodies
SG11201508199QA (en) * 2013-04-05 2015-11-27 Claudia Zylberberg Matrix metalloproteinases and uses thereof
JP2016537433A (ja) 2013-11-26 2016-12-01 ギリアード サイエンシーズ， インコーポレイテッド 骨髄増殖性障害を処置するための治療
EP3102238A1 (en) 2014-01-20 2016-12-14 Gilead Sciences, Inc. Therapies for treating cancers
EP2985295A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
EP2985296A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
CR20170395A (es) 2015-03-04 2017-11-07 Gilead Sciences Inc Compuestos moduladores de receptor de tipo toll
CN105037553B (zh) * 2015-08-20 2018-04-17 内蒙古蒙元生物基因科技有限公司 一种能够检测癌症的免疫球蛋白
WO2017059224A2 (en) 2015-10-01 2017-04-06 Gilead Sciences, Inc. Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
CA2951911A1 (en) 2015-12-17 2017-06-17 Gilead Sciences, Inc. Tank-binding kinase inhibitor compounds
WO2017106566A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
CA3016081A1 (en) 2016-03-04 2017-09-08 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
EP3440113A1 (en) * 2016-04-08 2019-02-13 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
EP3325513A4 (en) 2016-06-13 2018-12-19 I-Mab Anti-pd-l1 antibodies and uses thereof
CA3029074A1 (en) 2016-06-22 2018-01-25 William Warren HARLESS Cancer treatment and metastasis inhibition using an anti-cancer stem cell agent in combination with a neu1 sialidase inhibitor or a cytokine inhibitor after primary cancer treatment
MA45848A (fr) 2016-08-04 2019-06-12 Gilead Sciences Inc Cobicistat destiné à être utilisé dans des traitements du cancer
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
JP6746776B2 (ja) 2016-09-02 2020-08-26 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体調節剤化合物
WO2018085069A1 (en) 2016-11-03 2018-05-11 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
WO2018097977A1 (en) 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
JP7141397B2 (ja) 2016-12-16 2022-09-22 ユニヴェルシテ・ドゥ・ボルドー Ｍｍｐ９インヒビター及び色素脱失障害の予防又は処置におけるその使用
NZ753714A (en) 2017-01-24 2023-03-31 I Mab Biopharma Co Ltd Anti-cd73 antibodies and uses thereof
JP2020508326A (ja) 2017-02-24 2020-03-19 ギリアド サイエンシズ， インコーポレイテッド ブルトン型チロシンキナーゼの阻害剤
TWI754011B (zh) 2017-02-24 2022-02-01 美商基利科學股份有限公司 布魯頓氏酪胺酸激酶之抑制劑
US10941178B2 (en) 2017-03-17 2021-03-09 Gilead Sciences, Inc. Method of purifying an antibody
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
WO2019017338A1 (ja) 2017-07-18 2019-01-24 第一三共株式会社 活性型ｍｍｐ－９結合ペプチド
WO2019123339A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
PL3752501T3 (pl) 2018-02-13 2023-08-21 Gilead Sciences, Inc. Inhibitory pd-1/pd-l1
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
JP2021523151A (ja) 2018-05-11 2021-09-02 ホスホレックス、インコーポレイテッド 負の表面電荷を有するマイクロ粒子及びナノ粒子
PL3793565T3 (pl) 2018-05-14 2022-05-02 Gilead Sciences, Inc. Inhibitory MCL-1
US10774071B2 (en) 2018-07-13 2020-09-15 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
EP3860717A1 (en) 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
CN112955435B (zh) 2018-10-24 2024-09-06 吉利德科学公司 Pd-1/pd-l1抑制剂
MY205142A (en) 2018-10-31 2024-10-03 Gilead Sciences Inc Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
TW202136261A (zh) 2018-10-31 2021-10-01 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
KR102707808B1 (ko) 2019-03-07 2024-09-19 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
JP7350872B2 (ja) 2019-03-07 2023-09-26 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ３’３’－環状ジヌクレオチドおよびそのプロドラッグ
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
WO2020255038A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
PH12021553256A1 (en) 2019-06-25 2022-08-08 Gilead Sciences Inc Flt3l-fc fusion proteins and methods of use
PL4045083T3 (pl) 2019-10-18 2024-05-13 Forty Seven, Inc. Terapie skojarzone do leczenia zespołów mielodysplastycznych i ostrej białaczki szpikowej
EP4052040A1 (en) 2019-10-31 2022-09-07 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
SI4081305T1 (sl) 2019-12-24 2025-03-31 Carna Biosciences, Inc. Spojine, ki modulirajo diacilglicerol kinazo
CN115087488A (zh) 2020-02-14 2022-09-20 震动疗法股份有限公司 与ccr8结合的抗体和融合蛋白及其用途
BR112022020769A2 (pt) 2020-05-01 2022-12-20 Gilead Sciences Inc Compostos de 2,4-dioxopirimidina de inibição de cd73
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
KR20240023629A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
KR20240023628A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
WO2023278491A1 (en) * 2021-06-28 2023-01-05 Releviate, Llc Mmp-9 antibodies and uses thereof
US20230183216A1 (en) 2021-10-28 2023-06-15 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CR20240173A (es) 2021-10-29 2024-06-20 Gilead Sciences Inc Compuestos de cd73
US20230203202A1 (en) 2021-12-08 2023-06-29 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
WO2023107954A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
EP4452414A2 (en) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
HUE069263T2 (hu) 2022-03-17 2025-02-28 Gilead Sciences Inc Ikarosz cink-ujj család degradálói és azok alkalmazása
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
IL316058A (en) 2022-04-21 2024-11-01 Gilead Sciences Inc Compounds modulate KRAS G12D
IL317958A (en) 2022-07-01 2025-02-01 Gilead Sciences Inc CD73 compounds
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
CN120225509A (zh) 2022-12-22 2025-06-27 吉利德科学公司 Prmt5抑制剂及其用途
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025076280A1 (en) 2023-10-05 2025-04-10 Ashibio, Inc. Methods and compositions for treating mmp-9 mediated disorders
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
EP0685557B1 (en) 1993-11-30 1998-08-12 Fuji Yakuhin Kogyo Kabushiki Kaisha Novel metalloprotease and dna coding for the same
US5612030A (en) 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
AU770718B2 (en) 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
US7101975B1 (en) 1999-07-13 2006-09-05 University Of Southern California Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins
ATE435031T1 (de) 1999-07-13 2009-07-15 Univ Southern California Methode und zusammensetzung zur angiogenese- inhibierung mit antagonisten gegen mmp-9 und beta1-integrine
AU2002235692A1 (en) 2001-02-23 2002-09-04 Biophage Inc. Methods and compositions for preventing and treating neutrophil-mediated diseases
SE0102298D0 (sv) 2001-06-27 2001-06-27 Astrazeneca Ab Crystal structure of enzyme and uses thereof
WO2003006006A1 (en) 2001-07-09 2003-01-23 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
AU2002352089A1 (en) 2001-11-23 2003-06-10 Universite Catholique De Louvain Medical use of antibodies directed against human matrix metalloproteinases or related tissue proteinases for the treatment of abnormal uterine bleeding and endometriosis
US20040115194A1 (en) 2002-09-06 2004-06-17 Yi Wang Method of treatment of asthma using antibodies to complement component C5
WO2004076614A2 (de) 2003-02-27 2004-09-10 Bernd Hinzmann Humane nukleinsäuresequenzen aus prostatakarzinomen
ES2433440T3 (es) * 2003-04-04 2013-12-11 Yeda Research And Development Co. Ltd. Anticuerpos contra MMP2 o MMP9 y composiciones farmacéuticas que contienen los mismos útiles para inhibir la actividad de dichas metaloproteínas
WO2006037513A1 (en) 2004-10-09 2006-04-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with matrix metalloproteinase 9 (mmp9)
WO2007094842A2 (en) 2005-12-02 2007-08-23 Genentech, Inc. Binding polypeptides and uses thereof
CA2613204A1 (en) 2005-06-29 2007-01-11 Rules-Based Medicine, Inc. Methods and kits for the diagnosis of acute coronary syndrome
WO2007144781A2 (en) 2006-04-21 2007-12-21 Diagnotech Pty. Ltd. Diagnostic methods and kits utilizing antibodies for metalloproteases
WO2008088864A2 (en) 2007-01-18 2008-07-24 The Trustess Of Columbia University In The City Of New York Matrix metalloproteinase-9-related methods
KR20090113908A (ko) * 2007-02-23 2009-11-02 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 금속단백질 활성 억제용 항체 및 이를 함유하는 약학적 조성물
TW200911835A (en) 2007-06-08 2009-03-16 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
CA2695969A1 (en) 2007-08-15 2009-02-19 Yeda Research & Development Co. Ltd. Regulators of mmp-9 and uses therof
CA2707637A1 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
AU2009222048A1 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 binding proteins
WO2009111508A2 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
EP2350305A4 (en) * 2008-10-22 2013-03-06 Dyax Corp COMBINATION TREATMENTS WITH PROTEASE BINDING PROTEINS FOR INFLAMMATORY DISEASES
WO2010059543A1 (en) 2008-11-20 2010-05-27 Merck Sharp & Dohme Corp. Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
US8697078B2 (en) 2010-01-27 2014-04-15 Yeda Research And Development Co. Ltd. Antibodies that inhibit metalloproteins
US20110261695A1 (en) * 2010-04-23 2011-10-27 Xiaoming Zhao System and method for network congestion control
US8377443B2 (en) * 2010-08-27 2013-02-19 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
EA201491599A1 (ru) 2012-02-29 2015-05-29 Джилид Байолоджикс, Инк. Антитела к матриксной металлопротеиназе 9
US9550836B2 (en) 2012-02-29 2017-01-24 Gilead Biologics, Inc. Method of detecting human matrix metalloproteinase 9 using antibodies

Also Published As

Publication number Publication date
SG188224A1 (en) 2013-04-30
KR101930179B1 (ko) 2018-12-17
TR201910348T4 (tr) 2019-08-21
US8501916B2 (en) 2013-08-06
IL255300A0 (en) 2017-12-31
EP2608809A4 (en) 2015-04-01
AP3948A (en) 2016-12-21
KR101518144B1 (ko) 2015-05-28
US20160159923A1 (en) 2016-06-09
KR101881724B1 (ko) 2018-07-24
US20160122437A1 (en) 2016-05-05
US8377443B2 (en) 2013-02-19
EP2608809B1 (en) 2019-05-22
US20180086845A1 (en) 2018-03-29
CL2013000535A1 (es) 2014-03-21
ZA201301338B (en) 2016-07-27
BR112013004579A2 (pt) 2016-02-10
KR20180014245A (ko) 2018-02-07
NZ701444A (en) 2016-06-24
EA031729B1 (ru) 2019-02-28
MX2013002323A (es) 2013-07-29
CN104530238B (zh) 2019-11-26
MA34527B1 (fr) 2013-09-02
US20130023654A1 (en) 2013-01-24
US20130281675A1 (en) 2013-10-24
HK1208688A1 (en) 2016-03-11
CN103140240B (zh) 2015-01-21
US9120863B2 (en) 2015-09-01
IL224614A (en) 2017-11-30
CR20130132A (es) 2013-05-29
UA109908C2 (xx) 2015-10-26
PE20131376A1 (es) 2013-11-25
KR20170030659A (ko) 2017-03-17
JP2016020389A (ja) 2016-02-04
MX342413B (es) 2016-09-28
KR20150004936A (ko) 2015-01-13
US9260532B2 (en) 2016-02-16
JP2013539365A (ja) 2013-10-24
BR112013004579B1 (pt) 2019-03-12
ZA201507081B (en) 2017-02-22
AU2011293125A1 (en) 2013-04-18
AU2011293125B2 (en) 2015-02-05
KR20130063009A (ko) 2013-06-13
SI2608809T1 (sl) 2019-08-30
PH12013500347A1 (en) 2017-08-02
KR101827048B1 (ko) 2018-02-07
AP2013006743A0 (en) 2013-02-28
CN104530238A (zh) 2015-04-22
CN103140240A (zh) 2013-06-05
CA2808418A1 (en) 2012-03-01
EP2608809A2 (en) 2013-07-03
ECSP13012525A (es) 2013-05-31
JP5878538B2 (ja) 2016-03-08
NZ606880A (en) 2015-01-30
SG10201506703VA (en) 2015-10-29
CA2808418C (en) 2019-02-05
PT2608809T (pt) 2019-08-26
PH12016501691A1 (en) 2017-07-03
AP2016009448A0 (en) 2016-09-30
JP2017221216A (ja) 2017-12-21
US20130281676A1 (en) 2013-10-24
US20120135004A1 (en) 2012-05-31
ES2739505T3 (es) 2020-01-31
JP6198797B2 (ja) 2017-09-20
PL2608809T3 (pl) 2019-10-31
CO6680656A2 (es) 2013-05-31
WO2012027721A3 (en) 2012-08-16
JP6435381B2 (ja) 2018-12-05
WO2012027721A2 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
EA201491575A1 (ru) Антитела к матриксной металлопротеиназе 9
CY1123518T1 (el) Ανθρωπινα αντισωματα enanti-tau
CY1120951T1 (el) Ανθρωπινα αντισωματα enanti-tau
MX2011011754A (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b.
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
PE20150023A1 (es) Proteinas de union a antigeno st2
EA201790757A1 (ru) Связывающие антиген cd27l белки
AR083747A1 (es) Anticuerpos anti-il-23
CL2011003148A1 (es) Proteina biespecifica de union a antigeno, que comprende a)2 cadenas ligeras y 2 cadenas pesadas de un anticuerpo que se une especificamente a un antigeno y 2 fragmentos fab, b)dos fragmentos fab adicionales de un anticuerpo que se une especificamente a un segundo antigeno; metodo de preparacion; composicion farmaceutica y uso.
EA201001335A1 (ru) Антитела, направленные против ангиопоэтина-1 и ангиопоэтина-2, и их применение
MX2021005048A (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
EA201291065A1 (ru) Антитела против vla-4
MX2021009275A (es) Moleculas de union especificas.
EA201990895A1 (ru) Антитела к о1 и варианты их применения
EA201691414A1 (ru) Антитела к матриксной металлопротеиназе 9 и способы их применения
EA202191187A1 (ru) Антитела к ctla4, фрагменты антител, их иммуноконъюгаты и их применение
EA201992186A1 (ru) Антитела к par2 и пути их применения
TH148296B (th) แอนติบอดีต้านเมทริกซ์เมทัลโลโปรตีเนส 9 (Antibodies to matrix metalloproteinase 9)
CL2010000521A1 (es) Anticuerpo aislado o fragmento que bloquea la fijacion de la union de la proteina wise; secuencias de cdr de la cadena liviana y pesada; polipeptido inmunogenico de wise; composicion farmaceutica que comprende dicho anticuerpo.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU